Major funding boost to advance gene therapy to stimulate retinal regeneration

A/Prof Raymond Wong and Mirugen Pty Ltd have secured $4.5 million investment from Brandon Capital, Tin Alley Ventures, and the University of Melbourne Genesis Pre-Seed Fund. This investment support the commercial development of a gene therapy using cell reprogramming to stimulate retina regeneration. This research would potentially offer a novel treatment to restore vision in patients suffering from a number of retinal degenerative diseases.

Read more about Mirugen here: [Link]

Read the online news coverage here:

• Mirugen press release [Link]

• Media release by Brandon Biocatalyst [Link]

• Insight news [Link]

• Ophthalmology Times Europe [Link]

• Mivision the ophthalmic journal [Link]

• LeadsOnTrees [Link]

• Media release by Centre for Eye Research Australia [Link]

• BioInformant news [Link]